Anticancer agent 254
Based on 1 Customer Validation
Anticancer agent 254 (compound 10) is a dichloroacetic acid-loaded compound with enhanced antitumor activity against leukemia cells in vitro and better stability in vivo, and can be considered for preclinical evaluation of cancer inhibition.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.62%
- CAS No.: 1841421-67-7
- Formule: C12H18Cl6N4O3
- Masse moléculaire:479.01
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
0.34 mM
Compound: 10
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 26653539] |
| JVM-2 | IC50 |
0.41 mM
Compound: 10
|
Cytotoxicity against human JVM2 cells after 48 hrs by MTT assay
Cytotoxicity against human JVM2 cells after 48 hrs by MTT assay
|
[PMID: 26653539] |
| Maver1 | IC50 |
0.55 mM
Compound: 10
|
Cytotoxicity against human Maver1 cells after 48 hrs by MTT assay
Cytotoxicity against human Maver1 cells after 48 hrs by MTT assay
|
[PMID: 26653539] |
| PBMC | IC50 |
1.26 mM
Compound: 10
|
Cytotoxicity against human PBMC cells after 48 hrs by MTT assay
Cytotoxicity against human PBMC cells after 48 hrs by MTT assay
|
[PMID: 26653539] |
Chemical Information
-
CAS No. 1841421-67-7
-
Appearance Solid
-
Masse moléculaire 479.01
-
Formule C12H18Cl6N4O3
-
Color White to off-white
-
SMILES
ClC(C(NCCN(CCNC(C(Cl)Cl)=O)CCNC(C(Cl)Cl)=O)=O)Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
-
Fiche technique (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 254 Related Classifications
HY-119324 Related Classifications
Powered by Bioz